MARKET REPORT

Typhoid Fever - Pipeline Review, H1 2017

BioPortfolio
Life Science Healthcare and Pharmaceutical Market Research and Corporate Data
Typhoid Fever - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Typhoid Fever - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H1 2017, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 1, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-
registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)

**Reasons to buy**

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Additional Details**

**Publisher**: Global Markets Direct

**Reference**: GMDHC8988IDB

**Number of Pages**: 41

**Report Format**: PDF

**Publisher Information**: 
Table Of Contents for Typhoid Fever - Pipeline Review, H1 2017 [Report Updated: 28-02-2017]

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Typhoid Fever
  - Overview
- Therapeutics Development
  - Pipeline Overview
  - Pipeline by Companies
  - Pipeline by Universities/Institutes
- Typhoid Fever
  - Therapeutics Assessment
    - Assessment by Molecule Type
    - Typhoid Fever - Companies Involved in Therapeutics Development
    - GlaxoSmithKline Plc
    - Indian Immunologicals Ltd
    - Nanotherapeutics Inc
    - Prokarium Ltd
    - Protein Potential LLC
    - Sanofi Pasteur SA
    - Shantha Biotechnics Ltd
    - SK Chemicals Co Ltd
    - Zydus Cadila Healthcare Ltd
- Typhoid Fever - Drug Profiles
  - (paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
  - (paratyphoid + typhoid) vaccine - Drug Profile
  - (shigella + typhoid) vaccine - Drug Profile
  - (Streptococcal pneumonia + typhoid) vaccine - Drug Profile
  - (Streptococcal pneumonia + typhoid) vaccine - Drug Profile
  - Typhella - Drug Profile
  - typhoid vaccine - Drug Profile
  - typhoid vaccine - Drug Profile
  - typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
- Typhoid Fever - Dormant Projects
- Typhoid Fever - Discontinued Products
- Typhoid Fever - Product Development Milestones
- Featured News & Press Releases
  - Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
  - Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization
  - Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial Of Oral Typhoid Vaccine Candidate
  - Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
  - Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
  - Aug 30, 2005: Emergent Biosolutions’ Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
  - Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
- Appendix
  - Methodology
  - Coverage
  - Secondary Research
  - Primary Research
  - Expert Panel Validation
- Contact Us
- Disclaimer
How to Buy...

Typhoid Fever - Pipeline Review, H1 2017 [Report Updated: 28-02-2017]

**Option 1 - Online**
Go to our website and pay online with any major debit or credit card:

[https://www.bioportfolio.co.uk/product/47393](https://www.bioportfolio.co.uk/product/47393)

**Option 2 - Request a Proforma Invoice**
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ............................................................
Job Title: ................................................................
Your Email: ..........................................................
Your Contact Phone: ...............................................
Company Name: ....................................................
Address: ................................................................
Post/Zip Code: .....................................................
Country: .................................................................. 
P.O. Number: .........................................................
Any Other Instructions: ............................................

**Pricing Options:** (please tick one)
- $2000 | Single User Price
- $4000 | Site License Price
- $6000 | Enterprise License Price

**Payment Options:** (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ...........................................

**Option 3 - Phone Us on +44 (0)7887 945155**
We will be delighted to give you our personal attention.